Clinical characteristics of 178 cases of rifampicin mono-resistant or multidrug resistant tuberculosis
Objective To analyze the clinical characteristics of rifampicin resistant pulmonary tuberculosis patients and multidrug resistant pulmonary tuberculosis patients so as to provide the evidence for formulating the prevention and control measures and treatment plans for drug-resistant tuberculosis.Methods The data of pathogenic positive pulmonary tuberculosis patients having doctor visit in Anyang Tuberculosis Control and Prevention Institute from 2018 to 2022 were collected,and the basic information,laboratory and imaging indicators between single drug resistant and multidrug resistant pulmonary tuberculosis patients were compared.Results There were 178 cases of rifampicin mono-resistant and multi drug resistant tuberculosis patients,with the total drug resistance rate of 10.21％;64 cases were rifampicin mono-resistant,with the drug resistance rate of 3.67％,and 114 cases were multi drug resistant,with the drug resistance rate of 6.54％.From 2018 to 2022,the overall resistance rate of patients with rifampicin mono-resistance and multidrug resistance showed a decreasing trend(x2trend=6.220,P＜0.05).About the comparison of whether treatment had been interrupted in the past,the interruption rate of treatment in the multidrug-resistant group was 65.79％,higher than that in the rifampicin mono-resistant group,which was 43.75％(x2=8.166,P＜0.05);the comparison of white blood cell counts showed that in the multidrug-resistant group it was(9.39±2.88)×109/L,higher than that in the rifampicin mono-resistant group(8.03±2.62)×109/L(t=2.198,P＜0.05);the comparison of chest CT scores showed that in the multidrug-resistant group it was(13.50±2.13),higher than that in the rifampicin mono-resistant group(11.83±3.24)(t=0.560,P＜0.05).Conclusions The overall trend of drug resistant pulmonary tuberculosis in Anyang city shows a downward trend,and the chest imaging manifestation of multidrug resistant pulmonary tuberculosis patients is relatively serious.The standardized management and treatment of drug resistant tuberculosis patients should be strengthened.
Mono-resistant rifampicinMultidrug resistant pulmonary tuberculosisClinical features
NETL
NSTL
万方数据
